JP2002513019A - パロキセチン・アスコルビン酸塩 - Google Patents
パロキセチン・アスコルビン酸塩Info
- Publication number
- JP2002513019A JP2002513019A JP2000545858A JP2000545858A JP2002513019A JP 2002513019 A JP2002513019 A JP 2002513019A JP 2000545858 A JP2000545858 A JP 2000545858A JP 2000545858 A JP2000545858 A JP 2000545858A JP 2002513019 A JP2002513019 A JP 2002513019A
- Authority
- JP
- Japan
- Prior art keywords
- paroxetine
- present
- ascorbate
- solution
- paroxetine ascorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 40
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims abstract description 22
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229960002296 paroxetine Drugs 0.000 title claims abstract description 21
- 239000011668 ascorbic acid Substances 0.000 title claims abstract description 20
- 235000010323 ascorbic acid Nutrition 0.000 title claims abstract description 20
- 229940072107 ascorbate Drugs 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000012458 free base Substances 0.000 claims description 8
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- -1 dichloromethane Chemical compound 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9808896.6A GB9808896D0 (en) | 1998-04-25 | 1998-04-25 | Novel compound |
| GB9808896.6 | 1998-04-25 | ||
| PCT/GB1999/001244 WO1999055698A1 (en) | 1998-04-25 | 1999-04-23 | Paroxetine ascorbate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002513019A true JP2002513019A (ja) | 2002-05-08 |
Family
ID=10831008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545858A Pending JP2002513019A (ja) | 1998-04-25 | 1999-04-23 | パロキセチン・アスコルビン酸塩 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1089995A1 (id) |
| JP (1) | JP2002513019A (id) |
| KR (1) | KR20010042977A (id) |
| CN (1) | CN1297448A (id) |
| AP (1) | AP2000001963A0 (id) |
| AU (1) | AU3618499A (id) |
| BG (1) | BG104940A (id) |
| BR (1) | BR9909868A (id) |
| CA (1) | CA2330055A1 (id) |
| EA (1) | EA200001104A1 (id) |
| GB (1) | GB9808896D0 (id) |
| HU (1) | HUP0102116A3 (id) |
| ID (2) | ID26083A (id) |
| IL (1) | IL139081A0 (id) |
| NO (1) | NO20005352L (id) |
| PL (1) | PL343677A1 (id) |
| SK (1) | SK15912000A3 (id) |
| TR (1) | TR200003084T2 (id) |
| WO (1) | WO1999055698A1 (id) |
| ZA (1) | ZA200005912B (id) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005520803A (ja) * | 2002-01-09 | 2005-07-14 | エミスフェアー・テクノロジーズ・インク | ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| IL159280A0 (en) * | 2001-06-14 | 2004-06-01 | Teva Pharma | A process for preparing paroxetine hcl which limits formation of pink colored compounds |
| CN110607554B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备药物或药物中间体单晶或无定型物的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) * | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| DE3688827T2 (de) * | 1985-10-25 | 1994-03-31 | Beecham Group Plc | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. |
| US5276042A (en) * | 1993-04-16 | 1994-01-04 | Crenshaw Roger T | Treatment of premature ejaculation |
| ES2117557B1 (es) * | 1996-02-29 | 1999-07-01 | Ferrer Int | Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina. |
-
1998
- 1998-04-25 GB GBGB9808896.6A patent/GB9808896D0/en not_active Ceased
-
1999
- 1999-04-23 JP JP2000545858A patent/JP2002513019A/ja active Pending
- 1999-04-23 PL PL99343677A patent/PL343677A1/xx not_active Application Discontinuation
- 1999-04-23 BR BR9909868-7A patent/BR9909868A/pt not_active Application Discontinuation
- 1999-04-23 AP APAP/P/2000/001963A patent/AP2000001963A0/en unknown
- 1999-04-23 IL IL13908199A patent/IL139081A0/xx unknown
- 1999-04-23 EA EA200001104A patent/EA200001104A1/ru unknown
- 1999-04-23 CN CN99805160A patent/CN1297448A/zh active Pending
- 1999-04-23 ID IDW20002168A patent/ID26083A/id unknown
- 1999-04-23 ID IDW20002169A patent/ID26654A/id unknown
- 1999-04-23 SK SK1591-2000A patent/SK15912000A3/sk unknown
- 1999-04-23 EP EP99918151A patent/EP1089995A1/en not_active Withdrawn
- 1999-04-23 KR KR1020007011809A patent/KR20010042977A/ko not_active Application Discontinuation
- 1999-04-23 CA CA002330055A patent/CA2330055A1/en not_active Abandoned
- 1999-04-23 AU AU36184/99A patent/AU3618499A/en not_active Abandoned
- 1999-04-23 WO PCT/GB1999/001244 patent/WO1999055698A1/en not_active Application Discontinuation
- 1999-04-23 HU HU0102116A patent/HUP0102116A3/hu unknown
- 1999-04-23 TR TR2000/03084T patent/TR200003084T2/xx unknown
-
2000
- 2000-10-23 ZA ZA200005912A patent/ZA200005912B/en unknown
- 2000-10-24 NO NO20005352A patent/NO20005352L/no not_active Application Discontinuation
- 2000-11-13 BG BG104940A patent/BG104940A/bg unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005520803A (ja) * | 2002-01-09 | 2005-07-14 | エミスフェアー・テクノロジーズ・インク | ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体 |
| US7893297B2 (en) | 2002-01-09 | 2011-02-22 | Emisphere Technologies, Inc. | Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate |
Also Published As
| Publication number | Publication date |
|---|---|
| ID26654A (id) | 2001-01-25 |
| TR200003084T2 (tr) | 2001-02-21 |
| HUP0102116A2 (hu) | 2002-05-29 |
| SK15912000A3 (sk) | 2001-04-09 |
| KR20010042977A (ko) | 2001-05-25 |
| ID26083A (id) | 2000-11-23 |
| BR9909868A (pt) | 2000-12-19 |
| BG104940A (bg) | 2001-09-28 |
| EP1089995A1 (en) | 2001-04-11 |
| NO20005352D0 (no) | 2000-10-24 |
| IL139081A0 (en) | 2001-11-25 |
| WO1999055698A1 (en) | 1999-11-04 |
| GB9808896D0 (en) | 1998-06-24 |
| CN1297448A (zh) | 2001-05-30 |
| EA200001104A1 (ru) | 2001-04-23 |
| ZA200005912B (en) | 2001-12-19 |
| NO20005352L (no) | 2000-10-24 |
| AU3618499A (en) | 1999-11-16 |
| PL343677A1 (en) | 2001-08-27 |
| HUP0102116A3 (en) | 2002-12-28 |
| AP2000001963A0 (en) | 2000-12-31 |
| CA2330055A1 (en) | 1999-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60018040T2 (de) | Polymorphische kristalline formen von celecoxib | |
| WO2003013529A1 (en) | Paroxetine glycyrrhizinate | |
| KR20060135866A (ko) | 바제독시펜 아세테이트의 결정질 다형체 | |
| JP2007532548A (ja) | バゼドキシフェンアセテートの結晶質多形体 | |
| JP3518601B2 (ja) | エバスタイムまたはその類似体に基づく医薬組成物 | |
| EP1844017A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| JP2002505254A (ja) | パロキセチン塩 | |
| JP2002513019A (ja) | パロキセチン・アスコルビン酸塩 | |
| JP2003527424A (ja) | オキサゾリジノン錠剤製剤 | |
| JP2002511466A (ja) | マレイン酸パロキセチン | |
| JP2002513020A (ja) | Ｃｎｓ疾患治療のための１０−ショウノウスルホン酸パロキセチン | |
| MXPA00010439A (en) | Paroxetine ascorbate | |
| MXPA00010435A (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
| JP2951410B2 (ja) | 結晶（―）―３ｒ，４ｒ―トランス―７―メトキシ―２，２―ジメチル―３―フェニル―４―｛４―〔２―（ピロリジン―１―イル）エトキシ〕フェニル｝クロマン・酸性フマル酸塩 | |
| CZ20003942A3 (cs) | Askorbat paroxetinu | |
| JP2002531453A (ja) | パロキセチン塩酸塩アセトン溶媒和物の製法 | |
| WO2001014369A2 (en) | Process for the preparation of paroxetin.hcl | |
| CZ20003722A3 (cs) | Maleat paroxetinu | |
| AU2528899A (en) | Salts of paroxetine | |
| JP2002531550A (ja) | ５α−還元酵素の阻害剤としてのベンゾキノリン−３−オン誘導体の結晶形 | |
| MXPA00007719A (en) | Salts of paroxetine | |
| CZ20003941A3 (cs) | 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému | |
| MXPA00009884A (en) | Paroxetine maleate | |
| JP2002516611A (ja) | 結晶性（−）−３ｒ，４ｒ−トランス−７−メトキシ−２，２−ジメチル−３−フェニル−４−｛４−〔２−（ピロリジン−１−イル）エトキシ〕フェニル｝クロマン水素マレエート | |
| MXPA06011717A (en) | Crystalline polymorph of bazedoxifene acetate |